Literature DB >> 6292460

Immunization against the polyoma virus-induced tumor-specific transplantation antigen by early region mutants of the virus.

T Dalianis, G Magnusson, Y Ito, G Klein.   

Abstract

To investigate the relation between the polyoma tumor-specific transplantation antigen and the virus-coded proteins, mice were immunized by inoculation of a variety of viable polyoma virus mutants and then challenged with polyoma virus-induced tumors. Two classes of early region mutants were used. One class produces a normal small T-antigen and truncated middle and large T-antigens. The second class (hr-t mutants) forms a normal large T-antigen together with N-terminal fragments of small and middle T-antigens. All mutants, transforming as well as nontransforming, induced protection against polyoma virus tumors. However, there were quantitive differences between the mutants. The finding that an hr-t mutant could induce tumor rejection suggests that full-length middle and small T-antigens are not necessary for the induction of this response. Since intact middle T-antigen is the only virus-coded protein known to associate with the plasma membrane, the possibility must be considered that the polyoma virus tumor-specific transplantation antigen consists of cellular components.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6292460      PMCID: PMC256187     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Antigenic properties of other experimental tumors.

Authors:  G KLEIN; E KLEIN
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1962

2.  New classes of viable deletion mutants in the early region of polyoma virus.

Authors:  B E Griffin; C Maddock
Journal:  J Virol       Date:  1979-09       Impact factor: 5.103

3.  Construction and analysis of viable deletion mutants of polyoma virus.

Authors:  G Magnusson; P Berg
Journal:  J Virol       Date:  1979-11       Impact factor: 5.103

4.  Viral expression and immunogenicity of CBA mammary carcinomas and their hybrid lines with an L-cell derivative (A9HT).

Authors:  N Kuzumaki; R Ber; I A More; A J Cochran; F Weiner; G Klein
Journal:  Eur J Cancer       Date:  1979-10       Impact factor: 9.162

5.  Polyoma DNA: a physical map.

Authors:  B E Griffin; M Fried; A Cowie
Journal:  Proc Natl Acad Sci U S A       Date:  1974-05       Impact factor: 11.205

6.  Host range mutants of polyoma virus.

Authors:  T L Benjamin
Journal:  Proc Natl Acad Sci U S A       Date:  1970-09       Impact factor: 11.205

7.  Effects of antilymphocyte serum on virus oncogenesis.

Authors:  A C Allison; L W Law
Journal:  Proc Soc Exp Biol Med       Date:  1968-01

8.  Thirteen new mammary tumor cell lines from different mouse strains.

Authors:  N Kuzumaki; I A More; A J Cochran; G Klein
Journal:  Eur J Cancer       Date:  1980-09       Impact factor: 9.162

9.  Viable polyoma virus variant with two origins of DNA replication.

Authors:  G Magnusson; M G Nilsson
Journal:  Virology       Date:  1982-05       Impact factor: 3.616

10.  Coding potential and regulatory signals of the polyoma virus genome.

Authors:  E Soeda; J R Arrand; N Smolar; J E Walsh; B E Griffin
Journal:  Nature       Date:  1980-01-31       Impact factor: 49.962

View more
  3 in total

1.  A short peptide eluted from the H-2Kb molecule of a polyomavirus-positive tumor corresponds to polyomavirus large T antigen peptide at amino acids 578 to 585 and induces polyomavirus-specific immunity.

Authors:  Z Berke; S Palmer; T Bergman; D Wester; J Svedmyr; S Linder; H Jornvall; T Dalianis
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

2.  Antibodies against a nonapeptide of polyomavirus middle T antigen: cross-reaction with a cellular protein(s).

Authors:  Y Ito; Y Hamagishi; K Segawa; T Dalianis; E Appella; M Willingham
Journal:  J Virol       Date:  1983-12       Impact factor: 5.103

3.  Comparison of the DNA sequence of the Crawford small-plaque variant of polyomavirus with those of polyomaviruses A2 and strain 3.

Authors:  V M Rothwell; W R Folk
Journal:  J Virol       Date:  1983-11       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.